Stocks Health care DNLI
NASDAQ · Health careDenali Therapeutics Inc. (DNLI)
It posted a net loss of $314.4M. In fiscal 2025 capital spending exceeded operating cash flow by $422.1M. At September 30, 2026 it held $102.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Denali Therapeutics Inc.
- Net worth
- Denali Therapeutics Inc. has a market value (market cap) of $3.2B at the latest share price, and shareholders' equity of $926.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $512.5M.
- Cash flow
- In fiscal 2025 operations used $412.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Denali Therapeutics Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Denali Therapeutics Inc. does
Denali Therapeutics Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker DNLI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$512.5M | -$2.97 | -$422.1M |
| 2024 | $0 | -$422.8M | -$2.57 | -$363.6M |
| 2023 | $330.5M | -$145.2M | -$1.06 | -$370.9M |
| 2022 | $108.5M | -$326M | -$2.60 | -$262.5M |
| 2021 | $48.7M | -$290.6M | -$2.39 | -$219.9M |
| 2020 | $335.7M | $71.1M | $0.63 | $413.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Denali Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue was $17.8M; diluted EPS $0.37 versus -$0.74.
- November 3, 2026
- August 6, 2026
- August 6, 2026
- August 4, 2026Passive stake changed SCHEDULE 13G/A
- July 28, 2026
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- June 18, 2026
- June 4, 2026
- May 22, 2026
Insider trades
What the people running Denali Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $363.7K worth of shares in the last 90 days and bought none on the open market. Most of the selling (90%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 4, 2026 | Chin Peter ScottChief Medical Officer | Sold | 1,654 | $36.9K |
| September 2, 2026 | Thornberry NancyDirector | Soldpre-planned (10b5-1) | 10,824 | $247.3K |
| September 2, 2026 | Thornberry NancyDirector | Soldpre-planned (10b5-1) | 615 | $14.6K |
| September 1, 2026 | Schuth Alexander O.COFO and Secretary | Soldpre-planned (10b5-1) | 2,768 | $64.9K |
| August 12, 2026 | Watts Ryan J.President and CEO, Director | Gave as a giftindirect | 32,220 | - |
| August 11, 2026 | Schuth Alexander O.COFO and Secretary | Sold | 2,857 | $71.6K |
| June 3, 2026 | Flatley Jay TDirector | Received as pay | 6,408 | - |
| June 3, 2026 | Baker Bros. Advisors LPDirector | Received as payindirect | 6,408 | - |
Who owns DNLI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Investment Management, Inc.13G, passive | 10.2% | July 8, 2026 |
| Baillie Gifford & Co13G, passive | 7.5% | August 4, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 293 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 14,026,413 | +991,979 |
| Baillie Gifford & Co | 11,960,230 | -106,249 |
| State Street Corp | 7,049,304 | +777,303 |
| Temasek Holdings (Private) Ltd | 7,012,974 | 0 |
| Vanguard Portfolio Management LLC | 6,477,057 | +356,897 |
| Vanguard Capital Management LLC | 6,275,729 | +127,772 |
| Fmr LLC | 4,535,836 | -39,538 |
| Goldman Sachs Group Inc | 4,155,895 | -251,360 |
| Geode Capital Management, LLC | 3,973,342 | +246,228 |
| Holocene Advisors, LP | 3,905,225 | +709,796 |
| Baker Bros. Advisors LP | 3,734,336 | +2,641 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3,161,972 | -1,270,342 |
| UBS Group AG | 3,120,592 | +549,248 |
| Dimensional Fund Advisors LP | 2,860,604 | +168,429 |
| Norges Bank | 2,824,746 | new |
| Pictet Asset Management Holding SA | 2,791,206 | +232,341 |
| Capital Research Global Investors | 2,565,817 | +51,229 |
| Fisher Asset Management, LLC | 2,414,162 | -22,733 |
| Alliancebernstein L.P. | 2,984,807 | +91,189 |
| Nomura Asset Management International Inc. | 2,208,263 | +2,093,739 |
Insiders
11 insiders reported holding 6,508,761 shares in total, about $132.3M at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector | 3,422,3663,422,366 held indirectly |
| Watts Ryan J.President and CEO, Director | 2,417,2172,120,384 held indirectly |
| Schuth Alexander O.COFO and Secretary | 278,995 |
| Chin Peter ScottChief Medical Officer | 204,538 |
| Krognes Steve E.Director | 38,202 |
| Klein Peter SDirector | 33,941 |
| Cook Jennifer E.Director | 32,483 |
| Flatley Jay TDirector | 22,628 |
| Schenkein David PDirector | 21,665 |
| Thornberry NancyDirector | 19,686 |
Questions about DNLI
What does Denali Therapeutics Inc. do?
Denali Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as DNLI. Its shares trade on NASDAQ under the ticker DNLI.
What is Denali Therapeutics Inc.'s net worth?
Denali Therapeutics Inc. has a market value (market cap) of $3.2B at the latest share price, and shareholders' equity of $926.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Denali Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $314.4M.
When did Denali Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is Denali Therapeutics Inc.'s next earnings report?
Denali Therapeutics Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DNLI with
Follow DNLI
Get an email when Denali Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Denali Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.